First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-18

Study Completion Date

2024-10-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination with Durvalumab (MEDI4736) in Adult Subjects with Select Advanced Solid Tumors

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

NCT04999969

Locally Advanced or Metastatic Solid Tumours

ACTIVE_NOT_RECRUITING PHASE2

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

NCT02617277

Advanced Solid Tumours

ACTIVE_NOT_RECRUITING PHASE1

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

NCT04214093

Advanced Solid Tumors Lymphoma Multiple Myeloma +1 more

TERMINATED PHASE1

AZD8330 First Time in Man in Patients With Advanced Malignancies

NCT00454090

Cancer

COMPLETED PHASE1

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

NCT02537418

Solid Malignancies

ACTIVE_NOT_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase I, First in Human, multicentre, open-label, multiple arm study with dose escalations and expansions at selected doses. Dose-escalation will occur with AZD8701 in monotherapy (Part 1) and in combination with durvalumab (Part 3) in selected participants with HNSCC, TNBC, NSCLC, ccRCC, gastroesophageal cancer, melanoma, cervical cancer, small-cell lung cancer and/or participants with solid tumours who have demonstrated a response to prior PD-(L)1 treatment.

Disease specific expansions will occur with a selected dose of AZD8701 in participants with NSCLC (Part 2) and with a selected dose of AZD8701 and durvalumab in participants with TNBC and clear cell RCC (Part 4).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Clear Cell Renal Cell Cancer Non-Small-Cell Lung Cancer Triple Negative Breast Neoplasms Squamous Cell Cancer of Head and Neck Small Cell Lung Cancer Gastroesophageal Cancer Melanoma Cervical Cancer Advanced Solid Tumours

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

This is a Phase I, FIH, multicentre, open-label, multiple arm study. Dose-escalation will occur with AZD8701 in monotherapy and in combination with durvalumab in selected participants with HNSCC, TNBC, NSCLC, ccRCC, gastroesophgeal cancer, melanoma, cervical cancer, small-cell lung cancer and/or participants with solid tumours who have demonstrated a response to prior PD-(L)1 treatment.

Disease specific expansions will occur with a selected dose of AZD8701 in participants with NSCLC and with a selected dose of AZD8701 and durvalumab in participants with TNBC and clear cell RCC.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Open Label

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Monotherapy

Participants will receive AZD8701 intravenously, on Day 1, 3, 5 and 8 and then weekly for a maximum of 2 years.

Group Type EXPERIMENTAL

AZD8701

Intervention Type DRUG

FOXP3 antisense oligonucleotide

Combination Therapy

Participants will receive AZD8701 (intravenously, on Day 1, 3, 5 and 8 and then weekly) and durvalumab (MEDI4736) intravenously monthly for a maximum of 2 years.

Group Type EXPERIMENTAL

AZD8701

Intervention Type DRUG

FOXP3 antisense oligonucleotide

Durvalumab

Intervention Type BIOLOGICAL

anti PDL-1 monoclonal antibody

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD8701

FOXP3 antisense oligonucleotide

Intervention Type DRUG

Durvalumab

anti PDL-1 monoclonal antibody

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MEDI4736

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

The study is comprised of 2 main parts Monotherapy (AZD8701) and Combined Therapy (AZD8701 and Durvalumab).

* Histological or cytological confirmation of a solid, malignant tumour including HNSCC, TNBC, NSCLC, ccRCC, gastroesophageal cancer, melanoma, cervical cancer, SCLC, and/or participants with other solid tumours who have demonstrated a response to prior anti-PD-(L)1 treatment
* Participant with progressive disease that is refractory to standard therapies or for which no standard therapies exist and a clinical trial is the best option for next treatment based on prior response and/or tolerability to standard of care

Non Small Lung Cancer Participants who have received prior PD(L)1 treatment. Clear Cell Renal Cancer Participants who have not received prior PD(L)1 treatment.

Triple negative Breast Cancer participants who have who have not received prior PD(L)1 treatment.

* Must be 18 year old at the time of screening
* Body weight \> 35 kg
* Male and Female participants of childbearing potential must use effective methods of contraception
* Capable of giving signed informed consent
* ECOG performance status of 0 to 1
* A serum albumin \> 30g/L
* Life expectancy of \> 12 weeks
* At least 1 lesion, that qualifies as a RECIST 1.1 target lesion at baseline. Tumour assessment by CT scan or MRI must be performed within 28 days prior to treatment.
* Participants must provide a new or previous tumour sample
* Adequate organ system functions

Exclusion Criteria

* A condition that, in the opinion of the Investigator, would interfere with evaluation of the study intervention or interpretation of participant safety or study results
* History of allogeneic organ transplantation.
* Active or prior documented autoimmune or inflammatory disorders Uncontrolled intercurrent illness
* Significant cardiac disease
* History of another primary malignancy except for

1. Malignancy treated with curative intent and with no known active disease ≥ 5 years
2. non-melanoma skin cancer
3. Adequately treated carcinoma in situ without evidence of disease.
* Participant with previous or confirmed Covid 19 diagnosis requiring significant medical intervention
* Current clinical signs and symptoms consistent with COVID-19 or confirmed current infection by appropriate laboratory test within the last 4 weeks prior to screening
* Any major unresolved toxicity from previous anticancer therapy
* Known allergy or hypersensitivity to any of the study interventions or any of the study intervention excipients.

Prior/Concomitant Therapy

* Receipt of the last dose of anticancer therapy within 5 half-lives or ≤ 21 days prior to the first dose of study
* Prior treatment with potential Treg depletion therapies including agents targeting OX40 or CD357 (GITR) for 90 days prior to enrolment on study.
* Participants who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4:

1. Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy.
2. All AEs while receiving prior immunotherapy must have completely resolved or resolved to baseline
3. Must not have experienced a ≥ Grade 3 imAE or a neurologic or ocular imAE of any grade while receiving prior immunotherapy.
4. Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE
* Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug. b. The following are exceptions to this criterion:

1. Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection).
2. Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
3. Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)
* Any concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment
* Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study intervention.
* Major surgical procedure within 28 days prior to the first dose
* Participants receiving anticoagulation therapy with vitamin K antagonists (eg warfarin)
* Participation in another clinical study with study intervention administered in the last 30 days
* Female participants who are pregnant or breastfeeding or male and female participants of reproductive potential who are not willing to employ effective birth control

Minimum Eligible Age

18 Years

Maximum Eligible Age

101 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No